Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Inhaled Medications01:23

Inhaled Medications

388
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
388
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

305
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
305
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

575
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
575
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A Goal Without a Plan Is Just a Wish-Creating a Personalized Aftercare Plan for Breast Cancer Patients Supported by the Breast Cancer Aftercare Decision Aid.

Current oncology (Toronto, Ont.)·2025
Same author

Barriers to the use of direct access according to allied health professionals; an exploration among Dutch physiotherapists, dietitians, and health insurers.

BMC primary care·2025
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

Physical review letters·2025
Same author

Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.

Physical review letters·2025
Same author

Disentangling Sources of Momentum Fluctuations in Xe+Xe and Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2025

関連する実験動画

Updated: Sep 9, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K

喘息とCOPDの治療のためのインハラータの医療提供者の選択における環境影響の役割: 離散選択実験

I G Arslan1, M Vervloet2, E W de Bekker-Grob3,4,5

  • 1Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands. i.arslan@nivel.nl.

BMC primary care
|September 3, 2025
PubMed
まとめ

医療従事者は,喘息とCOPDのインハレーターを選択する際に,環境への影響よりも患者の成果を優先します. 臨床的要因は最重要であるが,吸入器の地球温暖化潜在力 (GWP) は処方者にとって重要な考慮事項である.

キーワード:
喘息についてCOPD について炭素フットプリント気候変動ディスクレート選択実験一般的な慣行吸入器優先順位

さらに関連する動画

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.4K

関連する実験動画

Last Updated: Sep 9, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.4K

科学分野:

  • 環境科学
  • 健康政策
  • 薬理学について

背景:

  • 圧力計量吸入器 (pMDIs) は,乾燥粉末吸入器 (DPI) や柔らかい霧吸入器のような代替品と比較して,高い地球温暖化潜在力 (GWP) を有しています.
  • 環境問題にもかかわらず,pMDIの処方量は増加しており,低GWPの選択肢を促進するための処方者の好みを理解する必要性を強調しています.
  • 環境に優しい吸入器の採用を奨励する戦略を策定するには,医療提供者の好みを理解することが不可欠です.

研究 の 目的:

  • 慢性阻害性肺疾患 (COPD) と喘息の患者に対する吸入器の選択における医療従事者の好みを調査する.
  • 臨床意思決定における地球温暖化潜在力 (GWP) を含む吸入器の属性の相対的な重要性を評価する.
  • 低GWP吸入器の使用を促進するための戦略を策定する.

主な方法:

  • 離散選択実験を用いた調査は,プライマリケア提供者に実施された.
  • 参加者には,使いやすさ,悪化の減少,副作用,自費費用,GWPで異なる様々なインハラースシナリオが提示されました.
  • 医療提供者選択におけるこれらの属性の相対的な重要性を分析するために多項ロジットモデルが使用されました.

主要な成果:

  • 悪化と副作用の減少は,GWP,コスト,システムタイプに次いで,吸入器の選択に影響を及ぼす最も重要な要因でした.
  • 提供者は,より高いGWPの吸入器が優れた臨床的利益 (例えば,悪化の減少) を提供した場合に選択する意思を示した.
  • 逆に 提供者は GWPが低い GWPの代替品を選ぶ傾向がありました

結論:

  • 臨床効果と患者の安全性は,COPDと喘息を治療する医療従事者がインハラータを選択する主な要因です.
  • 地球温暖化ポテンシャル (GWP) は,インハレーター選択における重要な,しかし二次的な要因であり,環境への影響の減少の可能性を示しています.
  • 持続的な吸入器の使用を促進する戦略は,GWPに関する明確な情報を提供することを優先し,臨床的有効性を確保することは,処方者にとって中心的な焦点です.